Table 3 Relapses during the study period
Etanercept*Placebo*p Value
Phase I (months 0–12):
    Patients with relapse (%)5077.8NS
    No. of relapses814NS
Phase II (months 13–15):
    Patients with relapse (%)25100NS
    No. of relapses11NS

  • *For phase I: etanercept n = 8, placebo = 9; for phase II: etanercept n = 4, placebo = 1.

  • NS, not significant.